Metamizol Zentiva

Metamizole sodium, the active ingredient in Metamizol Zentiva, is a pyrazolone analgesic presented as an injectable solution for intravenous use. It treats pain and fever, including postoperative pain and colic, in adult patients.

GNH USA supplies Metamizol Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metamizol Zentiva is a pyrazolone analgesic used in conditions where pain or fever require rapid control.

Pain: Provides analgesic relief for acute and moderate pain conditions. Fever: Reduces elevated body temperature in febrile states. Post‑operative pain: Controls surgical pain during the immediate recovery period. Colic: Alleviates severe abdominal cramping and associated discomfort.

Metamizol Zentiva may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Hypotension: transient drop in blood pressure after injection. - Nausea: mild gastrointestinal upset. - Dizziness: sensation of light‑headedness. - Injection site reactions: redness or mild pain at the site. - Flushing: temporary skin reddening. - Headache: mild to moderate headache.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells. - Anaphylactic reactions: life‑threatening allergic response. - Stevens‑Johnson syndrome: severe skin and mucous membrane disorder. - Blood dyscrasias: abnormal blood cell counts. - Severe hypotension: profound blood pressure fall requiring medical intervention.

Before using Metamizol Zentiva, consider the following safety measures.

Assess renal function: adjust use in patients with severe renal impairment. Monitor blood counts: regularly check for agranulocytosis during therapy. Avoid in known hypersensitivity: contraindicated for patients with prior allergic reactions to pyrazolones. Use cautiously in cardiovascular disease: risk of hypotensive episodes. Store at ambient temperature: keep in the original pack, protect from moisture and light.

Metamizol Zentiva can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent myelosuppressive agents: increased risk of severe bone‑marrow suppression. - Combination with other NSAIDs: heightened gastrointestinal toxicity. - Co‑administration with potent hypotensives: additive blood‑pressure lowering effects.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for enhanced bleeding risk. - Diuretics: may potentiate hypotensive response. - CYP450 substrates: possible alteration of metabolism, though data are limited.